Plain-English translation of NCT07166003 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is watching how patients with non-small cell lung cancer respond to neoadjuvant immunotherapy — a type of immune-boosting treatment given before other therapies. The study wants to understand whether surgery (and what type of surgery) works best after this initial treatment, or whether other options like radiation might be equally helpful. Researchers will follow 500 patients and carefully track their outcomes over time.
Doctors are still learning the best way to treat lung cancer after giving immunotherapy first. This medication works by helping your immune system fight cancer, but it's not yet clear whether patients do better with surgery afterward, or with treatments like radiation instead.
You likely qualify if…
You likely don't qualify if…
You will be observed as you receive your treatment plan — either surgery or non-surgical treatment like radiation — after your immunotherapy. Researchers will collect and analyze your medical information, imaging scans, and long-term health outcomes to understand which approach works best. This is an observational study, meaning doctors are watching and recording what happens naturally rather than assigning you randomly to a treatment group.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~500 participants
Started
April 2025
Primary completion
February 2027
Age range
18 Years – 79 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shugeng Gao, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.